2022
Dataset for the Reporting of Gestational Trophoblastic Neoplasia: Recommendations From the International Collaboration on Cancer Reporting (ICCR)
Hui P, Webster F, Baergen RN, Buza N, Cheung ANY, Kaur B, Ronnett BM, Shih IM, Seckl MJ, Lax SF, McCluggage WG. Dataset for the Reporting of Gestational Trophoblastic Neoplasia: Recommendations From the International Collaboration on Cancer Reporting (ICCR). International Journal Of Gynecological Pathology 2022, 41: s34-s43. PMID: 36305533, DOI: 10.1097/pgp.0000000000000876.Peer-Reviewed Original ResearchMeSH KeywordsCarcinomaFemaleGestational Trophoblastic DiseaseHumansNeoplasm StagingPathology, ClinicalPregnancyResearch ReportConceptsGestational trophoblastic neoplasiaTrophoblastic neoplasiaCancer reportingPathologic parametersTumor stagingCancer sitesPathology reportsPatient managementPatient careNeoplasiaNoncore elementsStagingTumor classificationPathologyInternational expertsDifferent populationsReportingCancer datasetsInternational collaborationData Set for the Reporting of Endometrial Cancer: Recommendations From the International Collaboration on Cancer Reporting (ICCR)
Matias-Guiu X, Selinger CI, Anderson L, Buza N, Ellenson LH, Fadare O, Ganesan R, Ip PPC, Palacios J, Parra-Herran C, Raspollini MR, Soslow RA, Werner HMJ, Lax SF, McCluggage WG. Data Set for the Reporting of Endometrial Cancer: Recommendations From the International Collaboration on Cancer Reporting (ICCR). International Journal Of Gynecological Pathology 2022, 41: s90-s118. PMID: 36305536, DOI: 10.1097/pgp.0000000000000901.Peer-Reviewed Original ResearchConceptsEndometrial cancerCancer reportingWorld Health Organization classificationFemale genital tumorsCancer patient careCommon cancerOrganization classificationResection specimensClinical managementGenital tumorsPatient careCancerMolecular classificationCancer diagnosisExpert cliniciansExpert pathologistsNoncore elementsMajor advancesDetailed recommendationsReportingCancer dataInternational collaborationPrognosisNeoplasmsTumors
2020
HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand
Buza N. HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand. Archives Of Pathology & Laboratory Medicine 2020, 145: 687-691. PMID: 32649220, DOI: 10.5858/arpa.2020-0207-ra.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaSerous carcinomaHER2 protein expressionHER2 testingNational Comprehensive Cancer Network clinical guidelinesProlonged progression-free survivalHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Gene amplificationStandard chemotherapy regimenProgression-free survivalProtein expressionAppropriate patient selectionGrowth factor receptor 2Recent clinical trialsSuccessful clinical outcomeHER2 protein overexpressionFactor receptor 2HER2 scoring criteriaHER2 therapyChemotherapy regimenEndometrial cancerClinical outcomesPatient selectionAggressive subtype